Kieran Gallahue - Net Worth and Insider Trading
Kieran Gallahue Net Worth
The estimated net worth of Kieran Gallahue is at least $19 Million dollars as of 2024-04-27. Kieran Gallahue is the CEO of ResMed Inc and owns about 56,922 shares of ResMed Inc (RMD) stock worth over $12 Million. Kieran Gallahue is the Director of Edwards Lifesciences Corp and owns about 70,920 shares of Edwards Lifesciences Corp (EW) stock worth over $6 Million. Kieran Gallahue is also the Director of Intersect ENT Inc and owns about 8,000 shares of Intersect ENT Inc (XENT) stock worth over $225,920. Details can be seen in Kieran Gallahue's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kieran Gallahue has not made any transactions after 2024-02-23 and currently still holds the listed stock(s).
Transaction Summary of Kieran Gallahue
Kieran Gallahue Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kieran Gallahue owns 5 companies in total, including Arena Pharmaceuticals Inc (ARNA) , Intersect ENT Inc (XENT) , and Envista Holdings Corp (NVST) among others .
Click here to see the complete history of Kieran Gallahue’s form 4 insider trades.
Insider Ownership Summary of Kieran Gallahue
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARNA | Arena Pharmaceuticals Inc | 2020-06-12 | director |
| XENT | Intersect ENT Inc | 2016-05-16 | director |
| NVST | Envista Holdings Corp | 2019-12-18 | director |
| EW | Edwards Lifesciences Corp | 2024-02-23 | director |
| RMD | ResMed Inc | 2011-01-05 | President & Global |
Kieran Gallahue Latest Holdings Summary
Kieran Gallahue currently owns a total of 3 stocks. Among these stocks, Kieran Gallahue owns 56,922 shares of ResMed Inc (RMD) as of January 5, 2011, with a value of $12 Million and a weighting of 66.14%. Kieran Gallahue owns 70,920 shares of Edwards Lifesciences Corp (EW) as of February 23, 2024, with a value of $6 Million and a weighting of 32.66%. Kieran Gallahue also owns 8,000 shares of Intersect ENT Inc (XENT) as of May 16, 2016, with a value of $225,920 and a weighting of 1.2%.
Latest Holdings of Kieran Gallahue
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RMD | ResMed Inc | 2011-01-05 | 56,922 | 218.06 | 12,412,411 |
| EW | Edwards Lifesciences Corp | 2024-02-23 | 70,920 | 86.43 | 6,129,616 |
| XENT | Intersect ENT Inc | 2016-05-16 | 8,000 | 28.24 | 225,920 |
Holding Weightings of Kieran Gallahue
Kieran Gallahue Form 4 Trading Tracker
According to the SEC Form 4 filings, Kieran Gallahue has made a total of 0 transactions in ResMed Inc (RMD) over the past 5 years. The most-recent trade in ResMed Inc is the sale of 32,590 shares on January 5, 2011, which brought Kieran Gallahue around $1 Million.
According to the SEC Form 4 filings, Kieran Gallahue has made a total of 2 transactions in Edwards Lifesciences Corp (EW) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Edwards Lifesciences Corp is the sale of 3,058 shares on February 23, 2024, which brought Kieran Gallahue around $267,911.
According to the SEC Form 4 filings, Kieran Gallahue has made a total of 0 transactions in Intersect ENT Inc (XENT) over the past 5 years. The most-recent trade in Intersect ENT Inc is the acquisition of 8,000 shares on May 16, 2016, which cost Kieran Gallahue around $101,120.
Insider Trading History of Kieran Gallahue
- 1
Kieran Gallahue Trading Performance
GuruFocus tracks the stock performance after each of Kieran Gallahue's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kieran Gallahue is 16.63%. GuruFocus also compares Kieran Gallahue's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kieran Gallahue within 3 months outperforms 3 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kieran Gallahue's insider trading performs compared to the benchmark.
Performance of Kieran Gallahue
Average Return
56.48%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 8.69 | 16.63 | 20.72 | 56.48 | 51.62 | 34.78 |
| Relative Return to S&P 500(%) | 6.59 | 10.62 | 13.21 | 37.98 | 40.03 | 22.65 |
Kieran Gallahue Ownership Network
Ownership Network List of Kieran Gallahue
Ownership Network Relation of Kieran Gallahue
Kieran Gallahue Owned Company Details
What does Arena Pharmaceuticals Inc do?
Who are the key executives at Arena Pharmaceuticals Inc?
Kieran Gallahue is the director of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .
Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arena Pharmaceuticals Inc Insider Transactions
Kieran Gallahue Mailing Address
Above is the net worth, insider trading, and ownership report for Kieran Gallahue. You might contact Kieran Gallahue via mailing address: Po Box 684369, Park City Ut 84068.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
